MISTMilestone Pharmaceuticals Inc.
Earnings
When Milestone Pharmaceuticals Inc. reports, what it reported each quarter, and how the stock took the results.
35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Mar 19, before the open
Fri, Mar 19, 2027in 122 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 10 – Apr 1
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
- Net income
- -$17.41M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $963.00K
- —
- Net income
- -$25.80M
- N/M
- EPS
- -$0.18
- N/M
- Revenue
- $559.00K
- —
- Net income
- -$28.61M
- N/M
- EPS
- -$0.21
- N/M
- Revenue
- $238.00K
- —
- Net income
- -$26.07M
- N/M
- EPS
- -$0.20
- N/M
- Revenue
- —
- —
- Net income
- -$17.41M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 13, 2026 · pre-market | Nov 13, 2026 | 44 d | 10-Q | $963.00K | — | -$0.18 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 · pre-market | Aug 12, 2026 | 43 d | 10-Q | $559.00K | — | -$0.21 | 11.0% | |
| Q1 2026 | Mar 31, 2026 | May 13, 2026 · pre-market | May 13, 2026 | 43 d | 10-Q | $238.00K | — | -$0.20 | 9.5% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 20, 2026 · pre-market | Mar 20, 2026 | 79 d | 10-K | — | — | — | 19.7% | |
| Q3 2025 | Sep 30, 2025 | Nov 12, 2025 · pre-market | Nov 12, 2025 | 43 d | 10-Q | $0.00 | — | -$0.12 | +0.5% | |
| Q2 2025 | Jun 30, 2025 | Aug 12, 2025 · pre-market | Aug 12, 2025 | 43 d | 10-Q | $0.00 | — | -$0.20 | +6.4% | |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 · pre-market | May 14, 2025 | 44 d | 10-Q | $0.00 | — | -$0.31 | 2.1% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 13, 2025 · pre-market | Mar 13, 2025 | 72 d | 10-K | — | — | — | +4.4% | |
| Q3 2024 | Sep 30, 2024 | Nov 12, 2024 · pre-market | Nov 12, 2024 | 43 d | 10-Q | — | — | -$0.14 | 3.6% | |
| Q2 2024 | Jun 30, 2024 | Aug 8, 2024 · after-hours | Aug 8, 2024 | 39 d | 10-Q | — | — | -$0.14 | +1.4% | |
| Q1 2024 | Mar 31, 2024 | May 13, 2024 · pre-market | May 13, 2024 | 43 d | 10-Q | — | — | -$0.21 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 21, 2024 · pre-market | Mar 21, 2024 | 81 d | 10-K | — | — | — | +4.0% | |
| Q3 2023 | Sep 30, 2023 | Nov 13, 2023 · pre-market | Nov 13, 2023 | 44 d | 10-Q | — | — | -$0.35 | 19.6% | |
| Q2 2023 | Jun 30, 2023 | Aug 10, 2023 · pre-market | Aug 10, 2023 | 41 d | 10-Q | — | — | -$0.37 | +1.6% | |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 · pre-market | May 11, 2023 | 41 d | 10-Q | — | — | -$0.35 | +9.0% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 29, 2023 · pre-market | Mar 29, 2023 | 88 d | 10-K | — | — | — | 2.3% | |
| Q3 2022 | Sep 30, 2022 | Nov 10, 2022 · after-hours | Nov 10, 2022 | 41 d | 10-Q | — | — | -$0.34 | +13.0% | |
| Q2 2022 | Jun 30, 2022 | Aug 10, 2022 · after-hours | Aug 10, 2022 | 41 d | 10-Q | — | — | -$0.39 | +2.9% | |
| Q1 2022 | Mar 31, 2022 | — | May 12, 2022 | 42 d | 10-Q | — | — | -$0.33 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 24, 2022 · pre-market | Mar 24, 2022 | 83 d | 10-K | — | — | — | +13.5% | |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 · pre-market | Nov 12, 2021 | 43 d | 10-Q | — | — | -$0.34 | +15.2% | |
| Q2 2021 | Jun 30, 2021 | — | Aug 11, 2021 | 42 d | 10-Q | — | — | $0.02 | — | |
| Q1 2021 | Mar 31, 2021 | — | May 17, 2021 | 47 d | 10-Q | — | — | -$0.30 | +2.8% | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | Mar 29, 2021 · after-hours | Mar 29, 2021 | 88 d | 10-K | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | Nov 13, 2020 | 44 d | 10-Q | — | — | -$0.40 | — | |
| Q2 2020 | Jun 30, 2020 | — | Aug 12, 2020 | 43 d | 10-Q | — | — | -$0.53 | 1.8% | |
| Q1 2020 | Mar 31, 2020 | — | May 14, 2020 | 44 d | 10-Q | — | — | -$0.67 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | — | Mar 6, 2020 | 66 d | 10-K | — | — | — | +5.2% | |
| Q3 2019 | Sep 30, 2019 | Nov 13, 2019 · pre-market | Nov 13, 2019 | 44 d | 10-Q | — | — | -$0.52 | 3.5% | |
| Q2 2019 | Jun 30, 2019 | Aug 13, 2019 · pre-market | Aug 13, 2019 | 44 d | 10-Q | — | — | -$1.04 | +2.2% | |
| Q1 2019 | Mar 31, 2019 | May 24, 2019 · after-hours | Jun 19, 2019 | 80 d | 10-Q | — | — | -$17.32 | — | |
| FY 2018 | ||||||||||
| Q4 2018derived | Dec 31, 2018 | — | — | — | — | — | — | — | — | |
| Q3 2018 | Sep 30, 2018 | — | — | — | — | — | — | -$20.16 | — | |
| Q2 2018 | Jun 30, 2018 | — | — | — | — | — | — | -$12.71 | — | |
| Q1 2018 | Mar 31, 2018 | — | — | — | — | — | — | -$15.57 | — | |
Earlier years, FY 2018 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Milestone Pharmaceuticals Inc. · CIK 1408443 · Engraved from SEC EDGAR